Labcorp, a leading global life sciences company, announced that it is now offering clonoSEQ®, the first U.S. FDA cleared test that can identify whether cancer cells remain in a patient’s body during and after treatment for lymphoid cancers, which develop within immune system cells. Labcorp is only U.S. commercial reference lab to offer clonoSEQ testing, […]

The post Labcorp To Offer First And FDA-Cleared Test For Monitoring Residual Blood Cancer Cells During And After Treatme first appeared on World Pharma Today.